ML Decision Model for G-NEC Adjuvant Therapy (NCT06663852) | Clinical Trial Compass
CompletedNot Applicable
ML Decision Model for G-NEC Adjuvant Therapy
China1,505 participantsStarted 2024-01-01
Plain-language summary
Gastric neuroendocrine carcinoma (G-NEC) is a rare and aggressive tumor originating from neuroendocrine cells in the stomach lining. It is characterized by a high propensity for recurrence and a generally poor prognosis. Due to its rarity, there is limited data and no established consensus on the optimal postoperative adjuvant therapy, making treatment decisions challenging for healthcare providers.
This study is a retrospective analysis focusing on evaluating survival rates, identifying prognostic factors, and formulating treatment recommendations for patients with G-NEC. By analyzing real-world clinical data, we aim to better understand the factors that influence patient outcomes and to develop evidence-based strategies for improving survival. Our goal is to provide clinicians with valuable insights and tools to make more informed treatment decisions, ultimately enhancing the quality of care and outcomes for patients with this challenging disease.
Who can participate
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* (1) patients who underwent radical surgery without any neoadjuvant therapy;
* (2) pathology confirmed NEC or mixed adenoneuroendocrine carcinoma (MANEC).
Exclusion Criteria:
* (1) history of other malignant neoplasms;
* (2) treatment with endoscopic submucosal dissection or endoscopic mucosal resection or thoracotomy;
* (3) incomplete clinical data (including pathological, adjuvant chemotherapy, and follow-up information);
* (4) receipt of alternative adjuvant treatment regimens;
* (5) death within 30 days postoperatively.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.